In 2017, it is estimated that more than 56,000 new cases of thyroid cancer will be diagnosed in the US—and approximately 75% of those patients will be women.
FDA granted traditional approval to Retevmo (selpercatinib) for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
